Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBCD34+-NK cells
- Development stage
- Unknown
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CBCD34+-NK cells are ex vivo expanded and differentiated natural killer (NK) cells generated from CD34+ hematopoietic stem and progenitor cells, typically isolated from umbilical cord blood[4][5][7]. These cell products are developed for adoptive cell immunotherapy, particularly for cancer and hematologic malignancies. NK cells produced in this way can exhibit cytolytic activity against tumor cells and are capable of rapid cytokine production (including interferon-γ and tumor necrosis factor-α) upon activation[4][7][5]. These cells are expanded using culture systems supplemented with cytokines such as IL-2 and IL-15, and they are intended for allogeneic use in immunotherapy applications[4][5][7]. Ex vivo produced CBCD34+-NK cells are functionally active, can be manufactured in large quantities, and are considered for "off-the-shelf" use due to their availability and standardized characteristics[4][5].
- Brand names
- CBCD34+-NK cells
- Other names
- cord blood CD34+-derived natural killer cellsumbilical cord blood-derived CD34+ NK cellsUCB-CD34+-NK cells
02
Targets
NKG2DL (NKG2D ligand family)
Beyond the preview
Go deeper on CBCD34+-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBCD34+-NK cells.